The diverse roles of sphingolipids in inflammatory bowel disease.
Chelsea L DollAshley J SniderPublished in: FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2024)
The incidence of inflammatory bowel disease (IBD) has increased over the last 20 years. A variety of causes, both physiological and environmental, contribute to the initiation and progression of IBD, making disease management challenging. Current treatment options target various aspects of the immune response to dampen intestinal inflammation; however, their effectiveness at retaining remission, their side effects, and loss of response from patients over time warrant further investigation. Finding a common thread within the multitude causes of IBD is critical in developing robust treatment options. Sphingolipids are evolutionary conserved bioactive lipids universally generated in all cell types. This diverse lipid family is involved in a variety of fundamental, yet sometimes opposing, processes such as proliferation and apoptosis. Implicated as regulators in intestinal diseases, sphingolipids are a potential cornerstone in understanding IBD. Herein we will describe the role of host- and microbial-derived sphingolipids as they relate to the many factors of intestinal health and IBD.
Keyphrases
- ulcerative colitis
- oxidative stress
- end stage renal disease
- healthcare
- ejection fraction
- randomized controlled trial
- systematic review
- public health
- transcription factor
- chronic kidney disease
- mental health
- newly diagnosed
- signaling pathway
- single cell
- cell death
- microbial community
- cell therapy
- rheumatoid arthritis
- stem cells
- systemic lupus erythematosus
- cell proliferation
- health information
- dna methylation
- disease activity
- cell cycle arrest
- bone marrow
- life cycle